FDA Enhances Recall of Over 160,000 Bottles of Thyroid Medication Due to Subpotent Ingredients

The U.S. Food and Drug Administration (FDA) has intensified its recall efforts for a widely prescribed thyroid drug following reports of insufficient active ingredient levels. This recall concerns more than 160,000 bottles of levothyroxine sodium, a medication used to treat hypothyroidism, which regulates thyroid hormone levels. Initially initiated on June 20, the recall was upgraded to a Class II classification on July 23, indicating a moderate risk to public health.

The recall was prompted by findings that the medications' content does not meet the approved specifications, with some pills containing less of the active ingredient than required. There have been no confirmed reports of illness directly linked to these subpotent pills, but the recall aims to prevent potential health issues associated with inadequate thyroid hormone replacement.

The affected products were manufactured by India-based Intas Pharmaceuticals for the American pharmaceutical company Accord Healthcare, based in North Carolina. The recall includes various doses, strengths, and package sizes, with specific lots and expiration dates identified, such as lot D2400536 expiring February 2026 and lot D2300325 expiring January 2026.

Thyroid hormone replacement therapy like levothyroxine is essential for managing hypothyroidism, a condition that, if untreated, can lead to serious complications like heart problems and high cholesterol. Patients taking these medications are advised to check their lot numbers and expiration dates and consult their healthcare providers for guidance.

For more detailed information about the recalled products, visit the FDA’s official database. Ongoing monitoring and regulatory actions continue to ensure medication safety for patients worldwide.